Marilyn E Coors1, Kristen M Raymond. 1. Center for Bioethics and Humanities bDivision of Substance Dependence, Department of Psychiatry, University of Colorado Denver, Aurora, Colorado, USA. marilyn.coors@ucdenver.edu
Abstract
OBJECTIVE: This qualitative research examined the ethical concerns regarding the psychosocial issues, research design and implementation, and application of psychiatric genetic research on substance use disorders (SUD) from multiple perspectives. METHODS: A literature review of the bioethics literature related to psychiatric genetics and focus groups explored the ethical implications of SUD genetic research. Twenty-six National Institute on Drug Abuse funded principal investigators in the field of psychiatric genetic research, nine adolescent patients in residential SUD treatment, and 10 relatives of patients participated in focus groups (held separately). The focus groups were recorded, transcribed, and the content was analyzed. The themes that emerged from the literature and the focus group transcripts were organized by using NVIVO7, a software package designed to manage, analyze, and compare narrative data. RESULTS: Investigators and the literature expressed similar concerns regarding the ethical concerns associated with psychiatric genetic research including violation of privacy, misunderstanding about psychiatric genetics, stigmatization, commercialization, discrimination, eugenics, consequences of research on illegal behavior, unforeseen consequences, altered notion of individual responsibility, and others. Patients and their relatives showed little familiarity with the ethical issues as identified by professionals and little concern regarding most of the potential risks. The exception was apprehension associated with potential criminal justice uses of stored genetic information, in particular enforced therapy and stigmatization, which elicited some concern from all perspectives. CONCLUSION: The challenge for further research is to identify risks and benefits of SUD research that are germane in a behaviorally disinhibited population and devise effective tools to communicate information to participants through an improved informed consent process.
OBJECTIVE: This qualitative research examined the ethical concerns regarding the psychosocial issues, research design and implementation, and application of psychiatric genetic research on substance use disorders (SUD) from multiple perspectives. METHODS: A literature review of the bioethics literature related to psychiatric genetics and focus groups explored the ethical implications of SUD genetic research. Twenty-six National Institute on Drug Abuse funded principal investigators in the field of psychiatric genetic research, nine adolescent patients in residential SUD treatment, and 10 relatives of patients participated in focus groups (held separately). The focus groups were recorded, transcribed, and the content was analyzed. The themes that emerged from the literature and the focus group transcripts were organized by using NVIVO7, a software package designed to manage, analyze, and compare narrative data. RESULTS: Investigators and the literature expressed similar concerns regarding the ethical concerns associated with psychiatric genetic research including violation of privacy, misunderstanding about psychiatric genetics, stigmatization, commercialization, discrimination, eugenics, consequences of research on illegal behavior, unforeseen consequences, altered notion of individual responsibility, and others. Patients and their relatives showed little familiarity with the ethical issues as identified by professionals and little concern regarding most of the potential risks. The exception was apprehension associated with potential criminal justice uses of stored genetic information, in particular enforced therapy and stigmatization, which elicited some concern from all perspectives. CONCLUSION: The challenge for further research is to identify risks and benefits of SUD research that are germane in a behaviorally disinhibited population and devise effective tools to communicate information to participants through an improved informed consent process.
Authors: Susan E Young; Andrew Smolen; John K Hewitt; Brett C Haberstick; Michael C Stallings; Robin P Corley; Thomas J Crowley Journal: Am J Psychiatry Date: 2006-06 Impact factor: 18.112
Authors: Thomas J Crowley; Susan K Mikulich; Kristen M Ehlers; Shannon K Hall; Elizabeth A Whitmore Journal: Am J Psychiatry Date: 2003-08 Impact factor: 18.112
Authors: Alma Husedzinovic; Dominik Ose; Christoph Schickhardt; Stefan Fröhling; Eva C Winkler Journal: Eur J Hum Genet Date: 2015-03-04 Impact factor: 4.246
Authors: Marilyn E Coors; Kristen M Raymond; Christian J Hopfer; Joseph Sakai; Shannon K McWilliams; Susan Young; Susan K Mikulich-Gilbertson Journal: Drug Alcohol Depend Date: 2015-12-21 Impact factor: 4.492
Authors: Marilyn Coors; Susan Mikulich-Gilbertson; Kristen Raymond; Shannon Stover; Thomas Crowley; Sandra Brown; Susan Tapert Journal: Am J Bioeth Date: 2008-10 Impact factor: 11.229
Authors: Melissa Raspa; Rebecca Moultrie; Laura Wagner; Anne Edwards; Sara Andrews; Mary Katherine Frisch; Lauren Turner-Brown; Anne Wheeler Journal: J Med Internet Res Date: 2020-05-21 Impact factor: 5.428